Gsa Capital Partners LLP Aerovate Therapeutics, Inc. Call Options Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AVTE
# of Institutions
79Shares Held
28.2MCall Options Held
116KPut Options Held
26.6K-
Ra Capital Management, L.P. Boston, MA9.19MShares$23.5 Million0.27% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA3.76MShares$9.62 Million0.74% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA2.24MShares$5.74 Million0.61% of portfolio
-
Atlas Venture Life Science Advisors, LLC1.8MShares$4.61 Million0.46% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.41MShares$3.61 Million0.05% of portfolio
About Aerovate Therapeutics, Inc.
- Ticker AVTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,448,100
- Market Cap $62.6M
- Description
- Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...